Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00612560 · ClinicalTrials.gov registry record · NA
Flaxseed, Aromatase Inhibitors and Breast Tumor Characteristics
A NA study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 28
- Enrollment target
NCT00612560: Completed NA study, sponsored by Roswell Park Cancer Institute.
NCT00612560 is a NA study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 28 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00612560, a NA study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 28 participants
- Enrollment target
Study Summary
The proposed study plans to examine the effect of flaxseed consumption, a phytoestrogen rich food, compared to aromatase inhibitors as a complementary approach to treating estrogen receptor positive breast cancer, as well as the effect of combined flaxseed and aromatase inhibitor therapy on breast cancer treatment. Because of the increasing use of both complementary and alternative approaches to treatment, and the use of aromatase inhibitors in the treatment of breast cancer, the proposed study has potential to provide important clinical information about the effect of foods high in phytoestrogens on a common endocrine therapy used in breast cancer.
Primary Outcome
Mean percentage of cells expressing estrogen receptor (ER-beta)
Interventions
- DRUG Placebo
- DRUG Anastrozole
- DIETARY_SUPPLEMENT flaxseed
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2007-11 |
| Est. Completion | 2014-04 |
| Phase | NA |
What the finished NCT00612560 record still lists
NCT00612560 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00612560 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00612560 about?
NCT00612560 is a clinical study titled "Flaxseed, Aromatase Inhibitors and Breast Tumor Characteristics". The proposed study plans to examine the effect of flaxseed consumption, a phytoestrogen rich food, compared to aromatase inhibitors as a complementary approach to treating estrogen receptor positive breast cancer, as well as the effect of combined flaxseed and aromatase inhibitor therapy on breast c...
What is the current status of trial NCT00612560?
This trial is currently completed. It is a NA study. The enrollment target is 28 participants. The study started on 2007-11. Estimated completion is 2014-04.
What interventions are being tested in trial NCT00612560?
The interventions under investigation include: Placebo (DRUG), Anastrozole (DRUG), flaxseed (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00612560?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00612560's enrollment target sits among peer trials
28 1704th of 2000 higher than 293 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia